Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer
Hui Zhang, Yuhang Liu, Guihao Zeng, Shuangshuang Hu, Haonan Li, Hong Wang · 2025
Read Cost-effectiveness of hypofractionated radiation therapy versus conventional radiation therapy for unresectable stage III non-small cell lung cancer by Hui Zhang, Yuhang Liu, Guihao Zeng, Shuangshuang Hu, Haonan Li, Hong Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750006.txt.
Description
Hui Zhang and co-authors compare the cost-effectiveness of two radiation schedules for advanced lung cancer that cannot be operated on. Their 2025 study weighs a moderately shortened schedule against the conventional longer one, both given with chemotherapy. The shorter schedule has shown better local control and survival hints in earlier studies, without clearly worse side effects.
The team built a three-stage model that follows patients over five years. It counts life years, quality-adjusted life years, and total costs for each schedule. Prior trials supplied the clinical inputs on control and toxicity. Economic value for this exact use had been largely unstudied, despite wide interest in shorter treatment. A clear cost picture helps hospitals and payers decide whether fewer, larger doses are worth adopting as standard care.
Catalog record
| CREATOR | Hui Zhang, Yuhang Liu, Guihao Zeng, Shuangshuang Hu, Haonan Li, Hong Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |